Academic Journal
Q2Drug Metabolism and Pharmacokinetics
About Drug Metabolism and Pharmacokinetics
About Drug Metabolism and Pharmacokinetics
Drug Metabolism and Pharmacokinetics is a peer-reviewed scholarly journal published by 3391 (Japan). It focuses on Q2. Publication coverage spans 2002-2026.
Key indicators: ISSN 1347-4367, 1880-0920; H-index 81.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (81): Strong citation impact — 81 articles cited at least 81 times each, reflecting solid influence.
Publishing in Drug Metabolism and Pharmacokinetics
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q2. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Drug Metabolism and Pharmacokinetics?
1347-4367, 1880-0920.
Who publishes Drug Metabolism and Pharmacokinetics?
3391.
What are Drug Metabolism and Pharmacokinetics's metrics?
H-index 81.
Is Drug Metabolism and Pharmacokinetics peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Pharmacogenetics and Drug Metabolism; Drug Transport and Resistance Mechanisms; Computational Drug Discovery Methods; Pharmacological Effects and Toxicity Studies; Drug-Induced Hepatotoxicity and Protection; Metabolism and Genetic Disorders.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
3,580.00 USD; 3,350.00 EUR; 2,870.00 GBP; 444,030.00 JPY
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Tyrosine kinase inhibitors suppress cytochrome P450 2C8 and 2J2 functions and their expression in renal cell carcinoma
Ayaka Kojima, Masayuki Nadai, Hiroshi Yamazaki, Miki Katoh et al.
2026-12 · DOI: 10.1016/j.dmpk.2026.101542Population pharmacokinetic analysis and exposure–response analysis of brexpiprazole in Japanese patients with agitation in Alzheimer's dementia
Koushi Higashi, Tomohiro Sasaki, Hikari Takahashi, Yosuke Kawai et al.
2026-12 · DOI: 10.1016/j.dmpk.2026.101549A novel scaling approach for human pharmacokinetic prediction of antibody-drug conjugates using minimal nonclinical data: Integration of monkey PK and in vitro data
Satoshi Nakayama, Nao Torimoto, Toshiyuki Kudo, Kiyomi Ito et al.
2026-10 · DOI: 10.1016/j.dmpk.2026.101543Evaluation of Food Effects on Oral Absorption from Lipid-Based Formulations Using an In Vitro Digestion–In Situ Absorption Model with a Physiologically Relevant Surface Area to Volume Ratio
Yusuke Tanaka, Shogo Sasaki, Hiroto Nishiura, Ko Imai et al.
2026-10 · DOI: 10.1016/j.dmpk.2026.101552Theoretical Analysis of Developmental Changes in Adenosine A2A Receptor Occupancy in Premature Infants Under Caffeine Therapy
Haruka Ide, Akane Hara, Ryosuke Fujihara, Kokoro Fukuzawa et al.
2026-10 · DOI: 10.1016/j.dmpk.2026.101555Development of a method for vancomycin monitoring in interstitial fluid using a novel porous microneedle array patch
Jo Terauchi, Taisei Kawamura, Jongho Park, Kiyomi Saito et al.
2026-10 · DOI: 10.1016/j.dmpk.2026.101546Physiologically-based pharmacokinetic modeling of coproporphyrin I, an endogenous OATP1B substrate, in cynomolgus monkeys: Bridging the inhibitory effect of rifampicin to humans
Takashi Yoshikado, Yukana Tomoda, Kouki Kasai, Reiki Toda et al.
2026-10 · DOI: 10.1016/j.dmpk.2026.101536Development and validation of LC–MS-based bioanalytical methods for oligonucleotide therapeutics: points to consider
Yuchen Sun, Kosuke Saito, Shin-ichiro Nitta, Ryoya Goda et al.
2026-10 · DOI: 10.1016/j.dmpk.2026.101545Characterization of unusual pyrazole ring-rearranged metabolites of DS-1971a specific to monkeys
Daigo Asano, Kazuyoshi Michiba, Kayoko Masuda, Takashi Ohnuki et al.
2026-10 · DOI: 10.1016/j.dmpk.2026.101550Microsomal and Hepatocyte Binding in Drug Discovery: Method Suitability and Lipophilicity-Based Predictions
Leonel Torrão, Gaëlle Chenal, Stephane Rodde, Birk Poller et al.
2026-10 · DOI: 10.1016/j.dmpk.2026.101556Translational limitations of a rat-derived hybrid pharmacokinetic–toxicodynamic model for chemotherapy-induced hematologic toxicity in humans
Shinji Kobuchi, Kenji Ikemura, Akihide Kobayashi, Masahiro Okuda et al.
2026-09 · DOI: 10.1016/j.dmpk.2026.101554Beyond Km and Vmax: a geometric framework for characterising enzyme modulation and validating kinetic data
Jonathan Salerno
2026-09 · DOI: 10.1016/j.dmpk.2026.101553Assessment of Infliximab Biotransformation in Patient Serum by Comparing Mass-Spectrometry and Ligand-Binding Assay Quantification
Sho Masui, Aoto Nakajima, Kodai Yajima, Takashi Shimada et al.
2026-09 · DOI: 10.1016/j.dmpk.2026.101551Differences in reactive metabolite formation and cytochrome P450 binding between acetaminophen and its bicyclo[1.1.1]pentane bioisostere
Minami Shibata, Ayato Mizuno, Tomoki Nakayoshi, Akifumi Oda et al.
2026-08 · DOI: 10.1016/j.dmpk.2026.101539Role of the arachnoid mater organic anion and cation transporters in the clearance of prostaglandin D2 and metformin from the cerebrospinal fluid in rats
Yuka Yaguchi, Kazunari Sasaki, Mai Inagaki, Tetsuya Terasaki et al.
2026-08 · DOI: 10.1016/j.dmpk.2026.101540Application of HepaSH cells for predicting cholestatic drug-induced liver injury via bile acid-dependent toxicity assay
Akinori Takemura, Shunya Naito, Yuichiro Higuchi, Shotaro Uehara et al.
2026-08 · DOI: 10.1016/j.dmpk.2026.101530Microfluidic post-insertion preparation and evaluation of RGD- and PEG-modified macrophage-derived small extracellular vesicles
Mizuki Umino, Longjian Geng, Yusuke Ushiroda, Makoto Matsumoto et al.
2026-08 · DOI: 10.1016/j.dmpk.2026.101538A permeability assay adapted for the assessment of very poorly permeable compounds in the bRo5 space
Paulina Page, Dallas Bednarczyk
2026-08 · DOI: 10.1016/j.dmpk.2026.101544Glutathione-reversible inactivation of aldehyde oxidase by hydralazine contributes to inter-lot inhibition variability in human hepatocytes
Lloyd Wei Tat Tang
2026-06 · DOI: 10.1016/j.dmpk.2026.101537Arylacetamide deacetylase deficiency potentiates ketoconazole-induced inhibition of triazolam metabolism in mice
Yuuki Otsuka, Mai Nagaoka, Miyu Watanabe, Masataka Nakano et al.
2026-06 · DOI: 10.1016/j.dmpk.2026.101529Reviews
Community Reviews
Version History
October 10, 2026 at 2:03 am
October 2, 2026